Clinical trial · Interventional
Imaging Study of Glioblastomas Treated With Avastin
Feasibility Study of Magnetic Resonance Spectroscopy and Dynamic Enhanced Cat Scan Imaging in Glioblastomas Treated With and Without Avastin
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): insufficient accrual
Summary
Brief summary (as posted)
This study aims to assess the effect of Avastin on brain vascularity and blood-brain permeability using dynamic contrast ct scans (DECT) and MRI imaging. Previous publications have documented the method by which DECT can determine alterations in vascular volume and tissue permeability within tumors and normal brain tissue. Functional maps of cerebral blood flow cerebral blood volume and permeability-surface area can be generated from the DECT studies to assess tumor perfusion. MRI spectroscopy analyzes brain chemistry to detect tumour versus edema versus normal brain. Thirty patients will receive MRI spectroscopy and DECT imaging at the time of presumed recurrence and 3 months later. 15 patients who do not receive Avastin and 15 patients who do receive Avastin as standard treatment for recurrence will be studied with DECT and MRI spectroscopy at baseline and then again in 3 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Gliomas | Glioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DECT | Device | — | UNRESOLVED |
| MR spectroscopy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- DECT/MR Spectroscopy +Avastin
- description
- -15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later
- interventionNames
- Device: DECT
- Device: MR spectroscopy
- type
- ACTIVE_COMPARATOR
- label
- DECT/MR Spectroscopy no Avastin
- description
- 15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
- interventionNames
- Device: DECT
- Device: MR spectroscopy
Primary outcomes (1)
- measure
- 3 Month Response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of glioblastoma with clinical or radiological evidence of progression as indicated by the RANO criteria 19 * Previous radiation and temozolomide chemotherapy * Patients must be receiving Avastin chemotherapy as second-line treatment if in the Avastin group * Study-specific consent Exclusion Criteria: * Failure to meet inclusion criteria * Pregnant or lactating patients * Allergy to iodine or CT contrast precludes DECT component of study * Claustrophobia precludes MR Spectroscopy component of study * Internal metal which would preclude an MRI scan
References
Publications (0)
Data not yet available